CareDx, Inc (CDNA) 10-Year Financial Performance & Capital Metrics

CDNA • • Industrial / General

HealthcareDiagnostics & ResearchMolecular Diagnostics & Genetic TestingSpecialized Testing Laboratories

AboutCareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.Show more

Revenue $334M +19.1%
EBITDA $61M +133.0%
Net Income $53M +127.6%
EPS (Diluted) 0.93 +126.3%
Gross Margin 67.16% +5.6%
EBITDA Margin 18.13% +127.7%
Operating Margin 12.21% +116.8%
Net Margin 15.74% +123.2%
ROE 16.43% +129.9%
ROIC 12.1% +123.5%
Debt/Equity 0.07 -42.8%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 80 (top 20%)
✓Strong 5Y sales CAGR of 21.3%

✗Weaknesses

No significant weaknesses identified

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y28.45%

5Y21.31%

3Y4.04%

TTM14.46%

Profit (Net Income) CAGR

10Y52.33%

5Y-

3Y-

TTM141.4%

EPS CAGR

10Y24.98%

5Y-

3Y-

TTM141.75%

ROCE

10Y Avg-28.35%

5Y Avg-14.35%

3Y Avg-17.79%

Latest10.31%

Peer Comparison

Specialized Testing Laboratories

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
RDNTRadNet, Inc.	5.64B	72.99	1951.60	13.18%	-0.65%	-0.97%	0.8%	1.53
IDXXIDEXX Laboratories, Inc.	56.86B	712.12	66.74	6.46%	24.65%	65.81%	1.4%	0.62
CDNACareDx, Inc	1.06B	20.57	22.12	19.07%	16.97%	19.53%	2.98%	0.07
TRIBTrinity Biotech plc	13.23M	0.71	-0.40	8.31%	-73.78%
NEOGNeogen Corporation	2.06B	9.46	-1.88	-3.2%	-68.47%	-28.64%		0.44
STRRStar Equity Holdings, Inc.	38.07M	10.96	-2.76	-66.93%	-5.36%	-8.98%		0.03
BGLCBioNexus Gene Lab Corp.	8.72M	3.69	-4.10	-2.66%	-24.27%	-33.7%		0.03
NEONeoGenomics, Inc.	1.66B	12.83	-4.14	11.65%	-16%	-13.54%		0.67

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	28.14M	40.63M	48.32M	76.57M	127.07M	192.19M	296.4M	321.79M	280.32M	333.79M
Revenue Growth %	0.03%	0.44%	0.19%	0.58%	0.66%	0.51%	0.54%	0.09%	-0.13%	0.19%
Cost of Goods Sold+	10.27M	21.12M	21.37M	32.99M	45.45M	63.12M	97.39M	112.21M	102M	109.63M
COGS % of Revenue	0.37%	0.52%	0.44%	0.43%	0.36%	0.33%	0.33%	0.35%	0.36%	0.33%
Gross Profit+	17.87M	19.51M	26.95M	43.58M	81.61M	129.08M	199.01M	209.58M	178.32M	224.16M
Gross Margin %	0.63%	0.48%	0.56%	0.57%	0.64%	0.67%	0.67%	0.65%	0.64%	0.67%
Gross Profit Growth %	-0.05%	0.09%	0.38%	0.62%	0.87%	0.58%	0.54%	0.05%	-0.15%	0.26%
Operating Expenses+	29.93M	44.28M	44.11M	58.14M	106.14M	151.6M	228.73M	286.81M	381.69M	183.39M
OpEx % of Revenue	1.06%	1.09%	0.91%	0.76%	0.84%	0.79%	0.77%	0.89%	1.36%	0.55%
Selling, General & Admin	20.6M	31.89M	31.72M	43.63M	75.43M	102.66M	152.21M	196.42M	201.2M	205.5M
SG&A % of Revenue	0.73%	0.78%	0.66%	0.57%	0.59%	0.53%	0.51%	0.61%	0.72%	0.62%
Research & Development	9.33M	12.38M	12.39M	14.51M	30.71M	48.94M	76.53M	90.39M	81.87M	72.41M
R&D % of Revenue	0.33%	0.3%	0.26%	0.19%	0.24%	0.25%	0.26%	0.28%	0.29%	0.22%
Other Operating Expenses	-188K	0	0	-178K	0	0	0	0	98.62M	-94.52M
Operating Income+	-11.93M	-37.33M	-20.29M	-15.58M	-24.53M	-22.53M	-29.73M	-77.23M	-203.36M	40.77M
Operating Margin %	-0.42%	-0.92%	-0.42%	-0.2%	-0.19%	-0.12%	-0.1%	-0.24%	-0.73%	0.12%
Operating Income Growth %	-10.55%	-2.13%	0.46%	0.23%	-0.57%	0.08%	-0.32%	-1.6%	-1.63%	1.2%
EBITDA+	-11.14M	-34.41M	-16.54M	-11.36M	-17.39M	-12.98M	-17.84M	-61.22M	-183.54M	60.52M
EBITDA Margin %	-0.4%	-0.85%	-0.34%	-0.15%	-0.14%	-0.07%	-0.06%	-0.19%	-0.65%	0.18%
EBITDA Growth %	-7.32%	-2.09%	0.52%	0.31%	-0.53%	0.25%	-0.37%	-2.43%	-2%	1.33%
D&A (Non-Cash Add-back)	796K	2.92M	3.76M	4.21M	7.14M	9.54M	11.88M	16.01M	19.82M	19.76M
EBIT	-12.06M	-24.77M	-18.34M	-15.58M	-24.53M	-17.71M	-29.73M	-77.23M	-104.74M	-53.75M
Net Interest Income+	-1.59M	-1.86M	-5.86M	-3.7M	985K	271K	160K	3.76M	11.87M	11.77M
Interest Income	0	0	0	0	985K	271K	160K	3.76M	11.87M	11.77M
Interest Expense	1.59M	1.86M	5.86M	3.7M	0	0	0	0	0	0
Other Income/Expense	-1.77M	-4.03M	-36.98M	-32.64M	585K	2.78M	-2.36M	997K	13.22M	12.09M
Pretax Income+	-13.71M	-41.36M	-57.27M	-48.22M	-23.95M	-19.75M	-32.09M	-76.23M	-190.14M	52.86M
Pretax Margin %	-0.49%	-1.02%	-1.19%	-0.63%	-0.19%	-0.1%	-0.11%	-0.24%	-0.68%	0.16%
Income Tax+	0	-1.61M	-1.71M	-1.43M	-1.98M	-1.04M	-1.43M	379K	141K	310K
Effective Tax Rate %	1%	0.95%	0.97%	0.97%	0.92%	0.95%	0.96%	1%	1%	0.99%
Net Income+	-13.71M	-39.47M	-55.47M	-46.76M	-21.97M	-18.71M	-30.66M	-76.61M	-190.28M	52.55M
Net Margin %	-0.49%	-0.97%	-1.15%	-0.61%	-0.17%	-0.1%	-0.1%	-0.24%	-0.68%	0.16%
Net Income Growth %	-18.55%	-1.88%	-0.41%	0.16%	0.53%	0.15%	-0.64%	-1.5%	-1.48%	1.28%
Net Income (Continuing)	-13.71M	-39.76M	-55.56M	-46.78M	-21.97M	-18.71M	-30.66M	-76.61M	-190.28M	52.55M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	279K	180K	0	0	0	0	0	0	0
EPS (Diluted)+	-1.16	-2.39	-2.38	-1.31	-0.52	-0.40	-0.59	-1.44	-3.54	0.93
EPS Growth %	-12.6%	-1.06%	0%	0.45%	0.6%	0.23%	-0.47%	-1.44%	-1.46%	1.26%
EPS (Basic)	-1.16	-2.39	-2.38	-1.31	-0.52	-0.40	-0.59	-1.44	-3.54	1.00
Diluted Shares Outstanding	11.86M	16.5M	23.33M	35.64M	42.15M	46.48M	52.24M	53.32M	53.76M	56.62M
Basic Shares Outstanding	11.82M	16.5M	23.31M	35.64M	42.15M	46.48M	52.24M	53.32M	53.76M	52.77M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	34.36M	26.67M	26.77M	81.11M	71.92M	273.1M	433.36M	387.85M	313.71M	351.83M
Cash & Short-Term Investments	29.89M	17.26M	16.89M	64.62M	38.22M	224.7M	348.49M	293.09M	235.42M	260.65M
Cash Only	29.89M	17.26M	16.89M	64.62M	38.22M	134.67M	348.49M	89.92M	82.2M	114.69M
Short-Term Investments	0	0	0	0	0	90.03M	0	203.17M	153.22M	145.96M
Accounts Receivable	2.37M	2.77M	2.99M	9.76M	24.06M	34.62M	59.76M	66.31M	51.06M	64.61M
Days Sales Outstanding	30.7	24.87	22.59	46.53	69.1	65.76	73.59	75.22	66.48	70.65
Inventory	766K	5.46M	5.53M	4.94M	6.01M	10.01M	17.19M	19.23M	19.47M	19.5M
Days Inventory Outstanding	27.22	94.37	94.43	54.69	48.29	57.9	64.41	62.56	69.68	64.93
Other Current Assets	1.34M	1.19M	1.35M	1.79M	0	0	0	9.22M	7.76M	7.07M
Total Non-Current Assets+	21.28M	50.06M	56.8M	49.58M	79.81M	95.41M	133.26M	155.14M	153.11M	139.22M
Property, Plant & Equipment	2.42M	2.93M	2.08M	4.13M	9.16M	25.93M	40.04M	70.22M	65.14M	57.89M
Fixed Asset Turnover	11.61x	13.86x	23.29x	18.52x	13.87x	7.41x	7.40x	4.58x	4.30x	5.77x
Goodwill	12.01M	13.84M	12.01M	12.01M	23.86M	23.86M	36.98M	37.52M	40.34M	40.34M
Intangible Assets	6.65M	33.12M	33.14M	33.25M	45.54M	44.35M	50.2M	43.05M	45.7M	38.18M
Long-Term Investments	147K	143K	9.58M	192K	0	0	0	0	0	0
Other Non-Current Assets	196K	-2.92M	-2.64M	-3.49M	1.26M	1.27M	6.05M	4.35M	1.94M	2.81M
Total Assets+	55.64M	76.73M	83.56M	130.7M	151.74M	368.51M	566.62M	542.99M	466.83M	491.05M
Asset Turnover	0.51x	0.53x	0.58x	0.59x	0.84x	0.52x	0.52x	0.59x	0.60x	0.68x
Asset Growth %	-0.09%	0.38%	0.09%	0.56%	0.16%	1.43%	0.54%	-0.04%	-0.14%	0.05%
Total Current Liabilities+	10.15M	40.83M	42.91M	19.5M	34.83M	69.22M	77.3M	75.97M	78.07M	89.37M
Accounts Payable	1.64M	3.06M	3.39M	4.71M	5.51M	9.65M	13.34M	9.94M	12.87M	7.69M
Days Payables Outstanding	58.41	52.96	57.92	52.13	44.21	55.82	49.99	32.34	46.06	25.59
Short-Term Debt	2.87M	22.85M	15.72M	0	0	0	0	0	0	0
Deferred Revenue (Current)	142K	42K	39K	39K	1000K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	2.9M	5.82M	18.77M	9.16M	15.39M	21.2M	32.77M	21.3M	26.24M	41.12M
Current Ratio	3.38x	0.65x	0.62x	4.16x	2.07x	3.95x	5.61x	5.10x	4.02x	3.94x
Quick Ratio	3.31x	0.52x	0.49x	3.91x	1.89x	3.80x	5.38x	4.85x	3.77x	3.72x
Cash Conversion Cycle	-0.5	66.27	59.11	49.09	73.18	67.83	88.02	105.43	90.1	109.99
Total Non-Current Liabilities+	15.99M	16.14M	46.61M	15.27M	17.91M	21.61M	23.44M	36.1M	127.43M	23.25M
Long-Term Debt	12.89M	1.1M	18.34M	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	2.37M	16.07M	17.39M	33.41M	28.28M	22.26M
Deferred Tax Liabilities	1.43M	6.06M	4.93M	2.97M	1.97M	1.3M	415K	0	136K	164K
Other Non-Current Liabilities	2.4M	8.22M	22.61M	11.61M	13.56M	4.25M	5.63M	2.7M	99.01M	819K
Total Liabilities	26.14M	56.97M	89.52M	34.77M	52.74M	90.83M	100.75M	112.08M	205.5M	112.62M
Total Debt+	15.75M	23.94M	34.06M	172K	5.39M	18.1M	21.35M	39M	34.22M	28.37M
Net Debt	-14.13M	6.69M	17.16M	-64.44M	-32.84M	-116.57M	-327.13M	-50.92M	-47.98M	-86.32M
Debt / Equity	0.53x	1.21x	-	0.00x	0.05x	0.07x	0.05x	0.09x	0.13x	0.07x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	0.47x
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-1.43x
Interest Coverage	-7.52x	-20.07x	-3.46x	-4.21x	-	-	-	-	-	-
Total Equity+	29.49M	19.76M	-5.95M	95.93M	99M	277.68M	465.88M	430.91M	261.33M	378.43M
Equity Growth %	-0.29%	-0.33%	-1.3%	17.11%	0.03%	1.8%	0.68%	-0.08%	-0.39%	0.45%
Book Value per Share	2.49	1.20	-0.26	2.69	2.35	5.97	8.92	8.08	4.86	6.68
Total Shareholders' Equity	29.49M	19.48M	-6.13M	95.93M	99M	277.68M	465.88M	430.91M	261.33M	378.43M
Common Stock	12K	21K	29K	41K	42K	49K	52K	52K	49K	51K
Retained Earnings	-173.08M	-212.55M	-268.02M	-311.85M	-333.81M	-352.53M	-383.19M	-460.44M	-678.27M	-626.24M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-11.87M	-3.66M	-2.35M	-4.28M	-5.21M	-2.1M	-4.67M	-7.5M	-6.96M	-8.57M
Minority Interest	0	279K	180K	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-9.75M	-16.52M	-14.31M	-4.01M	-2.77M	33.43M	-19.29M	-25.24M	-18.39M	38.05M
Operating CF Margin %	-0.35%	-0.41%	-0.3%	-0.05%	-0.02%	0.17%	-0.07%	-0.08%	-0.07%	0.11%
Operating CF Growth %	-1.91%	-0.69%	0.13%	0.72%	0.31%	13.07%	-1.58%	-0.31%	0.27%	3.07%
Net Income	-13.71M	-39.76M	-55.56M	-46.78M	-21.97M	-18.71M	-30.66M	-76.61M	-190.28M	52.55M
Depreciation & Amortization	796K	2.92M	3.76M	4.21M	7.14M	9.54M	11.88M	16.01M	19.82M	19.76M
Stock-Based Compensation	1.34M	2M	1.74M	7.14M	22.42M	23.4M	36.08M	46.55M	49.09M	66.41M
Deferred Taxes	-2K	-1.34M	-2.09M	-1.61M	0	0	0	0	566K	-187K
Other Non-Cash Items	-9K	18.18M	38.97M	33.9M	51K	1.8M	4.37M	3.03M	-3.61M	1.83M
Working Capital Changes	1.83M	1.47M	-1.13M	-871K	-10.41M	17.4M	-40.97M	-14.22M	106.03M	-102.31M
Change in Receivables	320K	1.05M	-109K	-3.97M	-12.68M	-10.4M	-24.42M	-6.66M	16.02M	-13.74M
Change in Inventory	-80K	492K	1.02M	363K	-1.27M	-3.2M	-6.93M	-2.86M	54K	-1.02M
Change in Payables	489K	-620K	292K	-168K	1.35M	4.39M	1.79M	-2.05M	2.9M	-5.11M
Cash from Investing+	-1.2M	-21.12M	-6.16M	-7.93M	-22.58M	-100.39M	47.71M	-228.5M	40.45M	-483K
Capital Expenditures	-1.2M	-549K	-186K	-7.24M	-3.35M	-10.36M	-20.26M	-24.33M	-9.24M	0
CapEx % of Revenue	0.04%	0.01%	0%	0.09%	0.03%	0.05%	0.07%	0.08%	0.03%	0.02%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	-20.57M	-59K	-5.2M	0	0	0	0	1.5M	-7.12M
Cash from Financing+	4.41M	24.93M	29.38M	50.27M	-132K	163.15M	185.64M	-4.54M	-29.61M	-5.61M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	46K	323K	19.67M	65.45M	40K	5.2M	-3.15M	-3.89M	-2.06M	-5.08M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-10.95M	-17.07M	-14.49M	-11.24M	-6.12M	23.07M	-39.55M	-49.57M	-27.63M	31.56M
FCF Margin %	-0.39%	-0.42%	-0.3%	-0.15%	-0.05%	0.12%	-0.13%	-0.15%	-0.1%	0.09%
FCF Growth %	-1.68%	-0.56%	0.15%	0.22%	0.46%	4.77%	-2.71%	-0.25%	0.44%	2.14%
FCF per Share	-0.92	-1.03	-0.62	-0.32	-0.15	0.50	-0.76	-0.93	-0.51	0.56
FCF Conversion (FCF/Net Income)	0.71x	0.42x	0.26x	0.09x	0.13x	-1.79x	0.63x	0.33x	0.10x	0.72x
Interest Paid	0	0	0	0	22K	10K	1K	8K	0	0
Taxes Paid	0	0	0	0	0	80K	14K	392K	738K	317K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-38.72%	-160.26%	-803.49%	-103.93%	-22.54%	-9.94%	-8.25%	-17.09%	-54.98%	16.43%
Return on Invested Capital (ROIC)	-56.57%	-133.95%	-80.84%	-54.73%	-37.68%	-14.87%	-14.87%	-22.33%	-51.41%	12.1%
Gross Margin	63.5%	48.02%	55.78%	56.92%	64.23%	67.16%	67.14%	65.13%	63.61%	67.16%
Net Margin	-48.7%	-97.14%	-114.79%	-61.06%	-17.29%	-9.74%	-10.34%	-23.81%	-67.88%	15.74%
Debt / Equity	0.53x	1.21x	-	0.00x	0.05x	0.07x	0.05x	0.09x	0.13x	0.07x
Interest Coverage	-7.52x	-20.07x	-3.46x	-4.21x	-	-	-	-	-	-
FCF Conversion	0.71x	0.42x	0.26x	0.09x	0.13x	-1.79x	0.63x	0.33x	0.10x	0.72x
Revenue Growth	3.07%	44.37%	18.93%	58.45%	65.95%	51.25%	54.22%	8.57%	-12.89%	19.07%

Revenue by Segment

	2016	2017	2018	2019	2020	2021	2022	2024
Service	-	-	-	-	-	-	-	249.38M
Service Growth	-	-	-	-	-	-	-	-
Product	-	-	-	-	-	-	-	40.78M
Product Growth	-	-	-	-	-	-	-	-
Digital And Other	-	-	-	-	9.28M	-	-	-
Digital And Other Growth	-	-	-	-	-	-	-	-
Royalty	-	-	300K	-	-	-	-	-
Royalty Growth	-	-	-	-	-	-	-	-
Post Transplant	-	33.69M	-	-	-	-	-	-
Post Transplant Growth	-	-	-	-	-	-	-	-
Pre Transplant	-	14.63M	-	-	-	-	-	-
Pre Transplant Growth	-	-	-	-	-	-	-	-
Care Dx	29.92M	-	-	-	-	-	-	-
Care Dx Growth	-	-	-	-	-	-	-	-
Olerup	10.71M	-	-	-	-	-	-	-
Olerup Growth	-	-	-	-	-	-	-	-

Revenue by Geography

	2016	2017	2018	2019	2020	2021	2022	2024
UNITED STATES	-	-	66.06M	104.06M	163.22M	258.41M	262.96M	317.73M
UNITED STATES Growth	-	-	-	57.51%	56.86%	58.32%	1.76%	20.83%
Europe	-	7.98M	7.6M	7.69M	7.47M	9.74M	9.08M	10.67M
Europe Growth	-	-	-4.74%	1.16%	-2.80%	30.30%	-6.77%	17.49%
Rest Of The World	-	1.73M	2.9M	494K	389K	873K	789K	5.38M
Rest Of The World Growth	-	-	67.96%	-82.99%	-21.26%	124.42%	-9.62%	582.38%
North America	33.22M	38.2M	-	-	-	-	-	-
North America Growth	-	15.02%	-	-	-	-	-	-
AUSTRALIA	-	411K	-	-	-	-	-	-
AUSTRALIA Growth	-	-	-	-	-	-	-	-
E M E A	6.99M	-	-	-	-	-	-	-
E M E A Growth	-	-	-	-	-	-	-	-
Latin America	424K	-	-	-	-	-	-	-
Latin America Growth	-	-	-	-	-	-	-	-

Frequently Asked Questions

Valuation & Price

CareDx, Inc (CDNA) has a price-to-earnings (P/E) ratio of 22.1x. This is roughly in line with market averages.

Growth & Financials

CareDx, Inc (CDNA) reported $358.0M in revenue for fiscal year 2024. This represents a 1651% increase from $20.5M in 2012.

CareDx, Inc (CDNA) grew revenue by 19.1% over the past year. This is strong growth.

Yes, CareDx, Inc (CDNA) is profitable, generating $60.8M in net income for fiscal year 2024 (15.7% net margin).

Dividend & Returns

CareDx, Inc (CDNA) has a return on equity (ROE) of 16.4%. This is reasonable for most industries.

CareDx, Inc (CDNA) generated $37.1M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...